Zhaoyang Meng,Bheemashankar A. Kulkarni,Angela Kerekes,Amit K J Mandal,Sara Esposite,David Belanger,Panduranga Adulla P. Reddy,Andrea Basso,Seema Tevar,Kimberly A. Gray,Jay A. Berzofsky,Elizabeth A. Smith,Doll Ronald J,M. Minhaj Siddiqui
Our continued effort toward the development of the imidazo[1,2-a]pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified.